Results 61 to 70 of about 3,163,010 (367)

KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells

Molecular Oncology, EarlyView.
We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock, Lina Benzien, Sandra Lange, Maja Huehns, Alexandra Runge, Catrin Roolf, Anett Sekora, Gudrun Knuebel, Hugo Murua Escobar, Christian Junghanss, Anna Richter   +10 more
wiley   +1 more source

TRANSCRIPTOME ANALYSES REVEAL NEW MARKERS FOR THE DIAGNOSIS AND TREATMENT OF KMT2A (MLL)-REARRANGED LEUKEMIA

Hematology, Transfusion and Cell Therapy, 2021
Introduction: KMT2A (MLL) gene rearrangements (KMT2A -r) are associated with diverse acute leukemias. Given the high number of KMT2A fusions, screening methods guide their detection regardless of partner gene.
BA Lopes, CP Poubel, CE Teixeira, A Caye-Eude, H Cavé, C Meyer, R Marschalek, M Boroni, M Emerenciano   +8 more
doaj  

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2019
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States.
M. Tallman, E. Wang, J. Altman, F. Appelbaum, V. Bhatt, D. Bixby, S. Coutre, M. de Lima, A. Fathi, M. Fiorella, J. Foran, Aric Hall, Meagan A. Jacoby, J. Lancet, T. Leblanc, G. Mannis, G. Marcucci, Mike G Martin, A. Mims, M. O'donnell, R. Olin, D. Peker, A. Perl, D. Pollyea, K. Pratz, T. Prebet, F. Ravandi, P. Shami, R. Stone, S. Strickland, M. Wieduwilt, K. Gregory, Lydia Hammond, Ndiya Ogba   +33 more
semanticscholar   +1 more source

Polyfunctional CD8+CD226+RUNX2hi effector T cells are diminished in advanced stages of chronic lymphocytic leukemia

Molecular Oncology, EarlyView.
CD226+CD8+ T cells express elevated levels of RUNX2, exhibit higher proliferation capacity, cytokines and cytolytic molecules expression, and migratory capacity. In contrast, CD226−CD8+ T cells display an exhausted phenotype associated with the increased expression of co‐inhibitory receptors and impaired effector functions.
Maryam Rezaeifar, Shima Shahbaz, Anthea C. Peters, Spencer B. Gibson, Shokrollah Elahi   +4 more
wiley   +1 more source

Proteomic Comparison of Acute Myeloid Leukemia Cells and Normal CD34⁺ Bone Marrow Cells: Studies of Leukemia Cell Differentiation and Regulation of Iron Metabolism/Ferroptosis

Proteomes
Acute myeloid leukemia (AML) is an aggressive bone marrow malignancy that can be cured only by intensive chemotherapy possibly combined with allogeneic stem cell transplantation.
Frode Selheim, Elise Aasebø, Håkon Reikvam, Øystein Bruserud, Maria Hernandez-Valladares   +4 more
doaj   +1 more source

Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population

Haematologica, 2009
Background Biphenotypic acute leukemia is a rare disorder that is difficult to diagnose. It displays features of both myeloid and lymphoid lineage. There is still a lack of studies in biphenotypic acute leukemia in a Chinese population. We present here a
Xiao-Qian Xu, Jian-Min Wang, Shu-Qing Lü, Li Chen, Jian-Min Yang, Wei-Ping Zhang, Xian-Min Song, Jun Hou, Xiong Ni, Hui-Ying Qiu   +9 more
doaj   +1 more source

Chimeric antigen receptor T-cell therapy for T-ALL and AML

Frontiers in Oncology, 2022
Non-B-cell acute leukemia is a term that encompasses T-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML). Currently, the therapeutic effectiveness of existing treatments for refractory or relapsed (R/R) non-B-cell acute leukemia ...
Wenwen Wei, Wenwen Wei, Dong Yang, Xi Chen, Dandan Liang, Liqun Zou, Xudong Zhao   +6 more
doaj   +1 more source

Mathematical Modeling of Leukemia Chemotherapy in Bone Marrow [PDF]

arXiv, 2022
Acute Lymphoblastic Leukemia (ALL) accounts for the 80% of leukemias when coming down to pediatric ages. Survival of these patients has increased by a considerable amount in recent years. However, around 15-20% of treatments are unsuccessful. For this reason, it is definitely required to come up with new strategies to study and select which patients ...
arxiv  

Inhibition of acyl‐CoA synthetase long‐chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction

Molecular Oncology, EarlyView.
Triacsin C inhibition of the acyl‐CoA synthetase long chain (ACSL) family decreases multiple myeloma cell survival, proliferation, mitochondrial respiration, and membrane potential. Made with Biorender.com. Multiple myeloma (MM) is an incurable cancer of plasma cells with a 5‐year survival rate of 59%.
Connor S. Murphy, Heather Fairfield, Victoria E. DeMambro, Samaa Fadel, Carlos A. Gartner, Michelle Karam, Christian Potts, Princess Rodriguez, Ya‐Wei Qiang, Habib Hamidi, Xiangnan Guan, Calvin P. H. Vary, Michaela R. Reagan   +12 more
wiley   +1 more source

Frequency of polymorphisms in the IKZF1 and CDKN2A/2B genes and descriptive analysis in pediatric patients with acute lymphoblastic leukemia: a multicenter hospital-based prevalence study in Rio De Janeiro

BMC Cancer
Background Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and B-cell ALL (B-ALL) is the most common subtype. The understanding of ALL has advanced significantly in recent years due to genomic sequencing, which has made it ...
Ariadne da Rocha Figueiredo, Thayana da Conceição Barbosa, Mariana Emerenciano, Marcelo Gerardin Poirot Land   +3 more
doaj   +1 more source